Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy.
Cristina ChiriacoChiara DoniniMarco CorteseStefano UghettoChiara ModicaIlaria MartinelliAlessia PromentLetizia VitaliLara FontaniMonica CasucciPaolo Maria ComoglioSilvia GiordanoDario SangioloValeria LeuciElisa VignaPublished in: Journal of experimental & clinical cancer research : CR (2022)
We set and validated at the pre-clinical level a MET-CAR immunotherapy strategy potentially beneficial for cancers not eligible for MET targeted therapy with inhibitory molecules, including those exhibiting primary or secondary resistance.
Keyphrases